anti-TNF-IR phase III

Update Il y a 4 ans
Reference: EUCTR2006-005330-20

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To determine the efficacy and safety of ocrelizumab versus placebo in reducing signs and symptoms of rheumatoid arthritis (RA), when used in combination with methotrexate (MTX) or leflunomide given either alone or in combination with other non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) in patients with active RA who have an inadequate response to at least one anti-TNF-α therapy.


Inclusion criteria

  • Rheumatoid Arthritis